Lung cancer is the cancer that has claimed the most lives worldwide for decades. Specifically, small cell lung cancer has been difficult to treat due to its ability to rapidly adapt and resist to treatment. In this study, public datasets of small cell lung cancer cells that became resistant after treatment with talazoparib or prexasertib were analyzed using bioinformatic tools to elucidate common processes that allow for treatment refraction. The reactive oxygen species (ROS) pathway and TGF-beta signaling pathway were prominent in the tissues treated with both treatment types. Shared genes contributing to these pathways in both treatments were studied for their role in the development of resistance. Seven genes were identified that should be further tested as potential targets to reverse treatment resistance.